Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2019-12-31 Director's Dealing
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
Director's Dealing 2019
Director's Dealing
2019-12-31 English
FORM 6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Anchiano Therapeutics Ltd., reporting its third quarter 2019 financial results. The text states that the financial statements are attached as Exhibit 99.1 and incorporated by reference, indicating that the actual financial data is included in the filing. The document length is 2188 characters, which is relatively short, but it explicitly states it is filing the quarterly financial results, not just announcing their publication. Form 6-K is used by foreign private issuers to report interim financial information and other material information. Given the content and context, this filing corresponds to an Interim / Quarterly Report (IR).
2019-11-21 English
SC 13G/A
Major Shareholding Notification
2019-11-18 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Anchiano Therapeutics Ltd., pursuant to SEC rules. It includes announcements about discontinuation of a clinical study, a press release of third quarter 2019 financial results, and a board appointment. The document is short (2839 characters) and primarily references attached press releases rather than containing detailed financial statements or comprehensive reports. It does not contain full financial data or detailed management discussion, but rather announcements and incorporated press releases. Therefore, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous filings that do not fit other specific categories.
2019-11-15 English
FORM 6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed by Anchiano Therapeutics Ltd., which is a report of a foreign private issuer pursuant to SEC rules. The content focuses on the appointment of Mr. Ofer Gonen to the Board of Directors, detailing his background, affiliations, and related party transactions. There is no financial data, earnings information, or detailed management discussion. The document is primarily an announcement of a change in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length (7048 characters) supports it being a full announcement rather than a brief notice or a report publication announcement.
2019-11-12 English
6-K
Board/Management Information Classification · 100% confidence The document is a Form 6-K filed by Anchiano Therapeutics Ltd., which is a report of a foreign private issuer pursuant to SEC rules under the Securities Exchange Act of 1934. The content specifically announces the resignation of a board member, Dr. Stephen Hoffman, from the company's Board of Directors. There is no financial data, earnings information, or detailed management discussion. The document is short (2192 characters) and primarily serves as an announcement of a board/management change. Therefore, it fits the category of Board/Management Information (MANG).
2019-10-28 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.